EUCTR2005-004384-33-GB进行中（未招募）1 期
A Phase 2, Open-Label, Single Dose Level, 24-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients with Fabry Disease - Phase 2 study of AT1001 in Fabry Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients must be adult males between 18 and 65 years of age (inclusive) and hemizygous for Fabry disease. Patients must have a confirmed diagnosis of Fabry disease with a documented missense gene mutation (individual or familial) and enhanceable enzyme activity (in vitro test: meeting specific criteria for enhancement). The patients must be naïve to ERT and other therapies, except for palliative therapies for the signs and symptoms of Fabry disease or must stop ERT for at least 30 weeks or up to 13 months. Patients must have end organ dysfunction, even minimal, demonstrated by either evidence of left ventricular hypertrophy documented by abnormal ECG and echocardiogram or by previous cardiac biopsy, or renal insufficiency documented by common clinical assessments such as creatinine and glomerular filtration rate or by renal biopsy. Patient agrees to be sexually abstinent or use a condom with spermicide when engaging in sexual activity during the course of the study and for a period of 30 days following their completion of the study. Patients must be previously untreated by ERT or substrate depletion for Fabry disease, or if ERT or other specific treatment for Fabry disease was administered, must stop ERT for at least 30 weeks or up to 13 months (in the judgment of the investigator, it must be considered safe for the patient to stop therapy for the duration of the study). Patients must be willing to undergo two renal and three skin biopsies. Patients must be willing and able to sign an informed consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The patient will be excluded from the study if: he has a history of organ transplant; there is evidence of significant disease other than Fabry disease (e.g., end-stage renal disease; heart disease [per clinical history, documented event, testing or class III/IV according to the New York Heart Association classification]; current diagnosis of cancer, except for basal cell carcinoma of the skin; diabetes (unless HbA1c <= 8); or neurological disease that impairs his ability to participate in the study); serum creatinine is greater than 2 on day -2; QTc interval is > 450 msec; pacemaker or other contraindication for MRI scanning; taking a medication prohibited by the protocol or any experimental therapy for any indication. Patients who participated in a clinical trial in the last 30 days. Patients who have any other condition which, in th opinion of the investigator would jeopardize the safety of the patient or impact the validity of the study results.
研究者
相似试验
进行中（未招募）
1 期
Investigation of the influence of ANX005 on the body of patients with primary cold agglutinin disease in terms of safety and tolerability. A Phase 2, single-center, open-label, repeat-dose study.Primary Cold Agglutinin Disease (CAD)EUCTR2020-005854-90-ATAnnexon, Inc.6
尚未招募
2 期
Evaluate the Safety, effectiveness and action of CRN04894 in the body in Participants with Congenital Adrenal Hyperplasia.CTRI/2023/12/060825Crinetics Pharmaceuticals Inc.
进行中（未招募）
不适用
The Study of an Investigational Drug, ALN-TTR02, for the Treatment of Transthyretin (TTR)-Mediated AmyloidosisTransthyretin mediated amyloidosis (ATTR)MedDRA version: 15.1Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 15.1Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-000467-24-SEAlnylam Pharmaceuticals, Inc.27
进行中（未招募）
不适用
The Study of an Investigational Drug, ALN-TTR02, for the Treatment of Transthyretin (TTR)-Mediated AmyloidosisTransthyretin mediated amyloidosis (ATTR)MedDRA version: 14.1Level: PTClassification code 10007509Term: Cardiac amyloidosisSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 14.1Level: PTClassification code 10019889Term: Hereditary neuropathic amyloidosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-000467-24-DEAlnylam Pharmaceuticals, Inc.27
进行中（未招募）
不适用
The Study of an Investigational Drug, ALN-TTR02, for the Treatment of Transthyretin (TTR)-Mediated AmyloidosisEUCTR2012-000467-24-ESAlnylam Pharmaceuticals, Inc.21